Krystal Biotech, Inc. KRYS Business Segments — Litigation settlement
Discontinued — last reported Q4 '25
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationSettlementExpense.
The official record: Krystal Biotech, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s business segments — litigation settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s business segments — litigation settlement?
- Krystal Biotech, Inc. (KRYS) reported business segments — litigation settlement of $0 in Q4 2025.
- What is the long-term trend for Krystal Biotech, Inc.'s business segments — litigation settlement?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s business segments — litigation settlement has grown at a -100.0% compound annual growth rate (CAGR), from $12.5M to $0.
- What does business segments — litigation settlement mean?
- The cost or gain resulting from the resolution of legal disputes.
- How do you interpret business segments — litigation settlement?
- Large settlements are generally negative for profitability, though they may resolve long-standing uncertainty regarding legal liabilities.
- How does business segments — litigation settlement compare across companies?
- Investors typically adjust for these items to evaluate the underlying 'normalized' earnings power of the business.